{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:51:41Z","timestamp":1760298701798},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s40256-013-0019-2","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T11:13:14Z","timestamp":1364296394000},"page":"121-128","source":"Crossref","is-referenced-by-count":9,"title":["Predicting the Impact of Polypill Use in a Metabolic Syndrome Population: An Effectiveness and Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"13","author":[{"given":"Ella","family":"Zomer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianna J.","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanfina","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","volume":"326","author":"NJ Wald","year":"2003","unstructured":"Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-25.","journal-title":"BMJ"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.109.873232","volume":"122","author":"E Lonn","year":"2010","unstructured":"Lonn E, Bosch J, Teo KK, et al. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078\u201388.","journal-title":"Circulation."},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","volume":"373","author":"S Yusuf","year":"2009","unstructured":"Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373:1341\u201351.","journal-title":"Lancet."},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archinte.164.3.249","volume":"164","author":"JE Manson","year":"2004","unstructured":"Manson JE, Skerrett PJ, Greenland P, et al. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med. 2004;164:249\u201358.","journal-title":"Arch Intern Med."},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1210\/jc.2006-0513","volume":"92","author":"SM Grundy","year":"2007","unstructured":"Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92:399\u2013404.","journal-title":"J Clin Endocrinol Metab."},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10198-007-0078-x","volume":"9","author":"X Sun","year":"2008","unstructured":"Sun X, Faunce T. Decision-analytical modeling in health-care economic evaluations. Eur J Health Econ. 2008;9:313\u201323.","journal-title":"Eur J Health Econ."},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM198701293160505","volume":"316","author":"SG Pauker","year":"1987","unstructured":"Pauker SG, Kassirer JP. Decision analysis. N Engl J Med. 1987;316:250\u20138.","journal-title":"N Engl J Med."},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00019053-200523060-00001","volume":"23","author":"A O\u2019Hagen","year":"2005","unstructured":"O\u2019Hagen A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modeling studies. Pharmacoeconomics. 2005;23:529\u201336.","journal-title":"Pharmacoeconomics."},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0168-8227(02)00025-6","volume":"57","author":"DW Dunstan","year":"2002","unstructured":"Dunstan DW, Zimmet PZ, Welborn TA, et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)\u2014methods and response rates. Diabetes Res Clin Pract. 2002;57:119\u201329.","journal-title":"Diabetes Res Clin Pract."},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"366","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J. The metabolic syndrome\u2014a new worldwide definition. Lancet. 2005;366:1059\u201362.","journal-title":"Lancet."},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","volume":"121","author":"KM Anderson","year":"1990","unstructured":"Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293\u20138.","journal-title":"Am Heart J."},{"key":"19_CR12","doi-asserted-by":"crossref","unstructured":"Zomer E, Liew D, Owen A, et al. Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms. Eur J Prev Cardiol 2012. doi: 10.1177\/2047487312449307 (Epub ahead of print).","DOI":"10.1177\/2047487312449307"},{"key":"19_CR13","unstructured":"Australian Institute of Health and Welfare 2011. National GRIM books. AIHW, 2011. http:\/\/www.aihw.gov.au\/national-grim-books ."},{"issue":"11","key":"19_CR14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PWF, for the REACH Registry Investigators, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197\u2013206.","journal-title":"JAMA"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","volume":"150","author":"U.S. Preventive Services Task Force","year":"2009","unstructured":"U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. Ann Intern Med. 2009;150:396\u2013404.","journal-title":"Ann Intern Med."},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","volume":"22","author":"P Clarke","year":"2002","unstructured":"Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340\u20139.","journal-title":"Med Decis Making."},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA.107.735340","volume":"117","author":"JP Greving","year":"2008","unstructured":"Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117:2875\u201383.","journal-title":"Circulation."},{"key":"19_CR18","unstructured":"Encyclopedia of Biostatistics 2nd ed. New York: Wiley; 2005."},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/0272989X0102100505","volume":"21","author":"S Woloshin","year":"2001","unstructured":"Woloshin S, Schwartz LM, Moncur M, et al. Assessing values for health: numeracy matters. Med Decis Making. 2001;21:382\u201390.","journal-title":"Med Decis Making."},{"key":"19_CR20","unstructured":"Australian Government: Department of Health and Ageing. Pharmaceutical benefits scheme (PBS). http:\/\/www.pbs.gov.au . Viewed 5 Sept 2011."},{"issue":"2","key":"19_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-8510(97)00015-8","volume":"41","author":"G Salkeld","year":"1997","unstructured":"Salkeld G, Phongsavan P, Oldenberg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy. 1997;41(2):105\u201319.","journal-title":"Health Policy"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1504\/IJSPM.2010.036018","volume":"6","author":"A Walker","year":"2010","unstructured":"Walker A, Butler JR. Economic model system of chronic diseases in Australia; a novel approach initially focusing on diabetes and cardiovascular disease. Int J Simul Process Model. 2010;6:137\u201351.","journal-title":"Int J Simul Process Model"},{"key":"19_CR23","first-page":"56","volume":"30","author":"T Huynh","year":"2004","unstructured":"Huynh T. Convenience care: a patient-centered mode duling. Physician Exec. 2004;30:56\u20138.","journal-title":"Physician Exec."},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","volume":"21","author":"F Sassi","year":"2006","unstructured":"Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Helath Policy Plan. 2006;21:402\u20138.","journal-title":"Helath Policy Plan."},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","volume":"7","author":"JL Severens","year":"2004","unstructured":"Severens JL, Milne RJ. Discounting health outcomes in economic evaluation; the ongoing debate. Value Health. 2004;7:397\u2013401.","journal-title":"Value Health."},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322\u201338.","journal-title":"Med Decis Making"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2337\/dc10-0843","volume":"33","author":"R Li","year":"2010","unstructured":"Li R, Zhang P, Barker LE, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabet Care. 2010;33:1872\u201394.","journal-title":"Diabet Care."},{"key":"19_CR28","unstructured":"World Health Organization. Choosing interventions that are cost effective (WHO-CHOICE). Geneva: World Health Organization; 2005."},{"key":"19_CR29","unstructured":"Vos T, Carter R, Barendregt J, et al. for the ACE-Prevention team. Assessing cost-effectiveness in prevention: ACE-prevention. Final report. University of Queensland, Brisbane and Deakin University, Melbourne 2010."},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2000.02248.x","volume":"95","author":"HT Sorensen","year":"2000","unstructured":"Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218\u201324.","journal-title":"Am J Gastroenterol."},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","volume":"348","author":"JP Kelly","year":"1996","unstructured":"Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413\u20136.","journal-title":"Lancet."},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296\u2013310.","journal-title":"Clin Ther."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0019-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-013-0019-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0019-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:24Z","timestamp":1559503704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-013-0019-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s40256-013-0019-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}